Company: REVB
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0000950170-25-083815
Chunk: 41

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 41
---
 eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business operations.

In any event, in order to finance its clinical trial program in addition to financings required to satisfy Nasdaq rules, the Company will be required to issue additional securities which may be in the form of common stock, preferred stock, convertible preferred stock, warrants to purchase the foregoing, convertible debt or other securities. There can be no assurance that any such financing will be available on terms attractive to the Company, if at all. Any such financing may be dilutive to the Company’s stockholders, which dilution may be substantial.

Reasons for the Stockholder Approval

Under applicable Nasdaq rules and the terms of the SPA, in no event may the Company issue to the holders shares of common stock equal to greater than 19.99% of the shares of common stock outstanding immediately prior to the SPA, unless the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap in accordance with applicable Nasdaq rules. Accordingly, this Proposal 6 is being submitted to the stockholders in order to comply with Rule 5635(d) of the Nasdaq Stock Market Rules.

Consequences of Not Approving this Proposal

After careful consideration, our Board of Directors believes that the issuance of the Class H Common Stock Warrants is in the best interest of the Company in order to give it the best chance of remaining on Nasdaq and continuing development of our product candidates. If our stockholders do not approve this proposal, we are required to hold a stockholder meeting every sixty (60) days until such approval is obtained. In addition, if this Proposal 6 is not approved by our stockholders we are prohibited from issuing, entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of our common stock or common stock equivalents until we receive such stockholder approval.

<div align='center'>24</div>

Vote Required and Board of Directors’ Recommendation

Nasdaq Listing Rule 5635(d) generally requires us to obtain stockholder approval prior to issuing more than 20% of our outstanding shares of common stock in connection with a transaction other than a public offering. The approval of Proposal 6 requires the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the special meeting.

<div align='center'>THE BOARD OF DIRECTORSUNANIMOUSLYRECOMMENDS A VOTE “FOR” PROPOSAL 6.

25